Bowave Pharmaceuticals Receives CDE's Implicit Approval for Phase I Clinical Trial of Hypertension-Targeting siRNA Therapy BW-00163

Sep 26, 2023 08:26 CST Updated 08:26

Argo

RNAi Drug Developer

According to the announcement on the CDE official website,Argo Biopharma(hereinafter referred to as "ArgoHangzhou Bolin Pharmaceutical Technology Co., Ltd., a subsidiary under the group, independently developedsiRNA New Drug BW-00163 InjectionReceived implied permission for clinical trials, this product will be used forTreatment of Hypertension。

Source: CDE Official Website

Argo Biopharma has two other siRNA drugs under development, respectively.BW-20805AndBW-00112, whose indications are respectivelyHereditary AngioedemaAndDyslipidemia。

Among themBW-00112 Injection for the Treatment of Dyslipidemia Receives Implied Clinical Trial Approval from CDE on July 21，Currently approved for clinical trial phase in China, the US, and AustraliaThe Phase I clinical trial of the drug conducted in Australia has completed the enrollment of subjects in all dosage groups.

BW-20805 Injection Granted CDE Clinical Trial Application Acceptance on July 28(Application No.: CXHL2300824). Currently, the product is undergoing Phase I clinical trials in Australia.

E.N.D

Previous article recommendations:

China's First National Standard for Human Stem Cells Released in Chongqing

The Fate of CAR-T Cells in the Human Body

Leadership of the National Health Commission Adjusted, New Head of the Discipline Inspection and Supervision Group Takes Office

Deep Belief Biosciences' Herpes Zoster mRNA Vaccine Receives FDA Clinical Trial Approval in the United States

All You Need to Know About Organoids: This Article Has Got You Covered

Detailed Explanation of AAV Linear Amplification Production Process

Saiyuan Biotech Completes New Round of Financing

Elon Musk's Brain-Computer Interface Human Trial Approved, Patient Recruitment Begins

Inspired by ChatGPT, Google DeepMind Predicts 71 Million Genetic Mutations! AI Deciphers Genetic Code in Science

Biopharmaceutical Financing Warms Up? 16 Financings of RMB 100 Million or More, Including Two Startups Completing IPOs Exceeding $500 Million

Shanghai Releases the 'Action Plan for Promoting Gene Therapy Scientific Innovation and Industrial Development in Shanghai (2023-2025)'

Collaborating with Nobel Laureate, Major Cell Therapy Platform Settles in Shenzhen

Samsung Biologics Signs New CDMO Order with BMS

Mengmu Bio Completes Tens of Millions of Yuan in Angel Financing

Produced in Just 1 Day! Myeloid LNP-mRNA In Vivo Cell Therapy Completes First Patient Dosing, Surpassing Traditional CAR-T

2023 White Paper on China's Cell Therapy Drug Industry

CDE Releases Two Technical Guidelines for Clinical Trials of Cell and Gene Therapy (Draft for Comments)

Chinese Scientists Successfully Grow Human Mid-stage Kidneys from Stem Cells in Pigs for the First Time

The Past and Present of the First Ophthalmic Gene Therapy Drug

Gene Editing Therapy Industry Research Report

1.5 Billion! Shenzhen Plans to Establish Cell and Gene Industry Fund

CAR-T Product of Reindeer Bio Priced at 1.166 Million Yuan

CAR-NK Therapy: The "Rising Star" in the Field of Cancer Immunotherapy

NMPA Releases New Regulations for Conditional Approval of Innovative Drugs (with Policy Interpretation)

Xiangya Hospital of Central South University Completes China's First Parkinson's Disease Gene Therapy Using AAV as a Gene Therapy Vector

Ophthalmic AAV Gene Therapy Drug Priced at 24.2 Million Yen Included in Japan's National Health Insurance

A Brief Discussion on the Similarities and Differences Between R&D QA and Production Site QA

The Era of Cell Therapy is Coming!

【Collectible Edition】Comprehensive Summary of Clinical Trial Processes

Heavyweight! The National Natural Science Foundation of China (NSFC) to Make Major Adjustments in Medical Research Funding!